Cocrystal Pharma, Inc. (COCP): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Cocrystal Pharma, Inc. (COCP) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001412486 0001412486 2026-06-03 2026-06-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Repor
How this was made
The 30-second read
Why it matters
The disclosure provides concrete incentive structure (salary, bonus, option strike at $1.05, and acceleration triggers) that may influence expectations for execution and potential M&A/strategic actions, but it does not provide new operating metrics.
Market read
Traders may reassess COCP’s governance/execution outlook due to the CEO transition, but the filing lacks pipeline or financial catalysts.
What to watch
Investors may focus on whether the incoming CEO’s prior GI-focused background translates to Cocrystal’s current development priorities, but the filing does not specify strategy changes.
Background
The 8-K (Item 5.02) reports a CEO appointment and related compensatory arrangements, replacing the company’s co-CEOs.
Ticker impact
Cocrystal Pharma appointed James Sapirstein as CEO and disclosed his base salary, bonus, and 10-year option grants with vesting/acceleration terms.
Likely modest, sentiment-neutral reaction unless investors view the CEO change as a clear strategic inflection.
The filing is a primary disclosure (8-K Item 5.02) but it does not include clinical/product updates or financial guidance; impact is mainly governance/expectations rather than fundamentals.
Market effects
Biopharma governance changes can affect perceived pipeline execution quality, but no sector-wide regulatory/clinical catalyst is disclosed here.
No specific regional market linkage beyond US-listed small-cap biotech sentiment.
No direct global operational or partnership update is provided.
Counterpoint
Equity compensation and vesting acceleration are standard; without pipeline/clinical milestones, the market may discount the CEO change as non-informative.
Key entities
- issuerCocrystal Pharma, Inc.
Nasdaq-listed biopharmaceutical company filing the 8-K regarding CEO appointment and compensation.
- executiveJames Sapirstein
Appointed Chief Executive Officer effective immediately; receives base salary, performance bonus, and option grants with vesting/acceleration terms.
- executiveSam Lee
Former co-CEO; continues as President and Chief Scientific Officer.
- executiveJames Martin
Former co-CEO; continues as Chief Financial Officer and signs the filing.

